e protective e ect of dexmedetomidine on bupivacaineinduced sciatic nerve in ammation is mediated by mast cells Abstract Purpose: is study was designed to assess the correlation between the neuroprotective e ect of dexmedetomidine and oxidative stress, neural in ammation and mast cell stability in rats with bupivacaine-induced sciatic nerve toxicity.
Bupivacaine is a long-acting local anesthetic with severe toxicity [1] . It can trigger apoptosis in nerve cells, depending on exposure time and concentration [2, 3] . Bupivacaine-induced apoptosis in the Schwann cell line is associated with reactive oxygen species (ROS) production [4] . Furthermore, in bupivacaine-induced injury, mast cells play an important role in the accumulation of neutrophils at the injury site [5] .
Schwann cells in peripheral nerve injury and activated macrophages express galectin-3, a galactose-speci c lectin formerly known as MAC-2 [6, 7] . Galectin-3, present on activated macrophages, is also a marker of Schwann cell damage. Matrix metalloproteinase 9 (MMP-9), which is increased in early phases of in ammation, is expressed by macrophages and other in ammatory cells [8] . In addition, MMP-9 inhibition is correlated with amelioration of in ammation. Matrix metalloproteinase 2 (MMP-2), which is increased in the late phase of inammation, is expressed by activated broblasts and is necessary for brosis [9, 10] . In other words, galectin-3 is a useful marker of activated macrophages and injured Schwann cells. MMP-9 is also a marker of in ammatory cells and macrophages and MMP-2 is a marker of activated broblast and is seen during the late phase of in ammation.
Recently, a new role other than allergic reaction has been noted for mast cells in in ammation and wound healing processes [11] [12] [13] . Mast cells are crucial sensors of cell injury and initiators of proin ammatory responses [14] . In addition, early studies suggest that the alpha-2 adrenergic receptor agonist clonidine may modulate mast cell function [15] [16] [17] [18] .
Compared with the alpha-2 adrenoceptor agonist, clonidine, dexmedetomidine has an eight-times higher a nity for the alpha-2 adrenoceptor [19] . In addition, perineural administration of dexmedetomidine ameliorates bupivacaine-induced perineural in ammation in rats [20] . It has been suggested that the neuroprotective e ects of dexmedetomidine depend on reduced ROS production in the hippocampus of rabbits a er a subarachnoid hemorrhage [21] .
In this study, the protective e ect of dexmedetomidine in bupivacaine-induced sciatic nerve injury was investigated to determine if it was associated with mast cell modulation.
Materials and Methods
Ethical approval for this study (Ethical Committee N° 2010/ 39) was provided by the Local Animal Ethical Committee of Dicle University, Diyarbakir, Turkey (Chairperson Prof. M. Serdar Kemaloğlu) on 27 October 2010. In this study, rats were handled in accordance with the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals prepared by the Local Animal Ethical Committee of Dicle University.
Forty adult female Wistar Albino rats, average weight 250 g, were obtained from the Laboratory Animals Facility of Dicle University.
Intraneural Injection into the Sciatic Nerve
e rats were divided randomly into ve groups with eight rats per group. In rats of all groups, the sciatic nerve was surgically exposed.. In groups II-V, rats received 0.3 ml intraneural injection into the right sciatic nerve. In group I (sham group), the rats received no injection. In group II (saline group), rats received an injection of 0.9% NaCl. In group III (bupivacaine group), rats received an injection of 0.2 ml of 0.5% bupivacaine hydrochloride (4 mg/kg; Marcaine™, produced by Eczacibaşi under license from Astra Zeneca PLC, Lüleburgaz, Turkey) and 0.1 ml of 0.9% NaCl. In group IV (dexmedetomidine group), rats received an injection of dexmedetomidine hydrochloride (20 µg/kg; Precedex™, Hospira, North Rocky Mount, NC 27801, USA). In group V (bupivacaine+dexmedetomid-ine group), rats received an injection of 0.2 ml of 0.5% bupivacaine hydrochloride (4 mg/kg) and 0.1 ml dexmedetomidine hydrochloride (20 µg/kg). Before procedures, all rats were anesthetized with intraperitoneal ketamine hydrochloride (80 mg/kg). e surgical area was shaved and disinfected with povidone iodine. All surgical procedures were performed under aseptic conditions and under a microscope. Surgical incision was made through the gluteal muscles in the prone position, as described elsewhere [22] . e sciatic nerve was exposed in the trifurcation region. Injections were performed 5 mm proximal to this point with a 30 G needle, intraneurally, either intra-or extra-fascicular. Injections were con rmed by the appearance of a fusiform swelling of the sciatic nerve. All injections were performed by the same researcher. A er injection, muscle and skin were closed and 14 days later the rats were sacri ced and sciatic nerve samples were collected for examination.
Measurement of Oxidative Stress
e excised sciatic nerve samples were weighed and immediately stored at -80ºC. Assays were performed on the supernatant of the prepared homogenate at 14,000 rpm for 30 min at +4ºC. e protein concentration of the tissues was measured by the Lowry method [41] . Using a modi ed version of the Eckerson method, serum paraoxonase-1 (PON-1) levels were measured spectrophotometrically [23] . e total antioxidant status (TAS) and total oxidant status (TOS) of supernatant fractions were evaluated using novel automated and colorimetric measurement methods developed by Erel [24, 25] . e TAS results are expressed as nmol Trolox equivalent/mg protein. 
Assessment of Galectin-3, MMP-2 and MMP-9 Levels with ELISA
In the sciatic nerve homogenate, galectin-3, MMP-2, and MMP-9 levels were assayed according to the product manual with rat galectin-3 ELISA kit (Catalog no. E90303Ra, Uscn Life Science Inc., China), rat MMP-2 ELISA kit (Catalog no. E90100Ra, Uscn Life Science Inc., China), and rat MMP-9 ELISA kit (Catalog no. E90553Ra, Uscn Life Science Inc., China), respectively.
Histopathological Evaluation
Sciatic nerve tissue samples were stored in 10% formaldehyde solution for 48 hours then embedded in para n and sliced with microtome into 5μm sections for histopathological analyses. Hematoxylin and eosin staining was performed and all samples were evaluated using a light microscope (Nikon ECLIPSE, 80i, Japan) by an expert pathologist, blinded to the study groups. Histopathological changes were scored (0=no in ammation, 1=small focal mild edema, 2=moderate edema and in ammation, 3=extensive edema and marked in ammation) [20] . Tissue samples were also stained with toloudine blue for detection of mast cells and were scored (0=no mast cells, 1=1-2 mast cells, 2=3-4 mast cells, 3=5 or more mast cells) by counting intraneural mast cells at x200 magni cation elds.
Statistics
Data are expressed as mean ± standard deviation (S.D.). e one-way analysis of variance (ANOVA) and post hoc multiple comparison tests (LSD) were performed on the data of biochemical and histopathological variables to examine di erences among groups. A P-value of <0.05 was considered statistically signi cant.
Results

E ects of Dexmedetomidine on Bupivacaine-induced Oxidative Stress in the Sciatic Nerve
TAS was almost equal in the sciatic nerve tissue of the sham, saline, dexmedetomidine and bupivacaine+dexmedetomidine groups, but was signi cantly lower in the bupivacaine group (Table 1) . ere was no di erence in TOS between the sham, saline and dexmedetomidine groups. TOS increased signicantly in the bupivacaine group but approached the sham level in the bupivacaine+dexmedetomidine group (Table 1) . PON-1 levels in the sham, saline and dexmedetomidine groups were similar, but decreased signi cantly in the sciatic nerve tissue of the bupivacaine group. PON-1 level in the bupivacaine+dex-medetomidine group was as high as in the sham group (Table 1). 
E ects of Dexmedetomidine on Bupivacaine-induced In ammation and Nerve Injury
e level of galectin-3, an indicator of Schwann cell injury and marker of activated macrophages, did not di er signi cantly in the sham, saline and dexmedetomidine groups; however, a markedly higher level of galectin-3 was observed in the bupivacaine group. Interestingly, in the bupivacaine+dexmedetomid-ine group, the galactin-3 level was at the level of the sham group (Table 1) . MMP-9, produced by macrophages and other in ammatory cells except T cells and mast cells, was detected in similar amounts in the sham, saline and dexmedetomidine groups. As expected, MMP-9 was produced in signi cantly higher amounts in the bupivacaine group; however, the MMP-9 level was similar to the sham group in the bupivacaine+dexmede-tomidine group (Table 1) . e level of MMP-2, which is produced by brocytes, was almost the same in the sham, saline and dexmedetomidine group, but signi cantly lower in the bupivacaine group. Surprisingly, the MMP-2 level in the bupivacaine+dexmedetomid-ine group was comparable to the value of the sham group (Table 1).
E ects of Dexmedetomidine on Bupivacaine-induced Mast Cell Recruitment
e degrees of in ammation and edema were lowest and almost the same in sham and saline groups. In the dexmedetomidine group, mild to moderate edema and cell in ltrate were detected in the sciatic nerve tissue. Edema and cell in ltrate in the sciatic nerve were marked in the bupivacaine group but less marked in the bupivacaine+dexmedetomidine group (Table 2) .
Besides in ammation and edema, the presence and appearance of mast cells were evaluated. In the sham and saline groups, mast cells were absent at the injury site. In the dexmedetomidine and bupivacaine+dexmedetomidine groups, the number of mast cells was signi cantly higher than in bupivacaine group (Table 2) . On the other hand, in the bupivacaine group, granulating and degranulated mast cells were evident than in the dexmedetomidine and bupivacaine+dexmedeto-midine groups (Fig. 1) . Figure 1B is a representative image of a large mast cell degranulation in the bupivacaine group. Stabilized mast cells were smaller in size in dexmedetomidine group than in the bupivacaine group (Fig. 1A and 1C ).
Discussion
Our objective was to study the possible protective e ects of dexmedetomidine in bupivacaine-induced sciatic nerve injury in rats. e therapeutic potential of dexmedetomidine, when it is combined with bupivacaine, may be associated with decreased oxidative stress (marked with increased TAS, decreased TOS and increased PON-1), decreased galactin-3, increased MMP-2 and decreased MMP-9. In ammatory scores and edema scores of the dexmedetomidine-injected group and bupivacaine-injected group were not signi cantly di erent. e existence of mast cells is clearly observed in all bupivacaine-and dexmedetomidine-injected groups; however, the mast cells in groups injected with dexmedetomidine are not degranulated.
Our results suggest that mast cells may play a prominent role in bupivacaine-induced nerve injury. New ndings about mast cells show that they are crucial in the early phases of tissue injury and in ammation. Mast cells are the rst cells recruited to the injury site and produce pro-in ammatory mediators selectively without degranulation for recruitment of neutrophils, macrophages and other monocytes [13] . e cytotoxic side e ect of bupivacaine on nerves and the presence of mast cells in bupivacaine-induced injury site are reported elsewhere [4, 5] . In parallel, this study is the rst to reveal accumulation of mast cells in bupivacaine-induced injury in the sciatic nerve (Fig. 1B) . In our study, an increased level of galectin-3 and high oxidative stress may be an indicator of the presence of macrophages in bupivacaine-induced sciatic nerve injury. High oxidative stress itself may be a re ection of the presence of neutrophils at the site. In addition to Schwann cells in peripheral nerve injury, it is well known that macrophages, particularly activated ones, express galactin-3 [6, 7, 26] . Moreover, during the phagocytosis process, phagocytes such as macrophages and neutrophils produce high levels of ROS; therefore, assessment of oxidative stress in tissue may supply information that is directly correlated to the number of phagocytes present at the injury region [27] [28] [29] . It has been suggested that mast cell density is strongly associated with expression of MMP-9 in chronic in ammation [30] . It has also been reported that MMP-9 plays a critical role in the progression of in ammation in the early phases, speci cally MMP-9 produced by macrophages and other in ammatory cells but not by T cells and mast cells [8] . MMP-2 is mostly produced by brocytes, which are known to be active in the late phases of the wound healing process [8, [31] [32] [33] . We show here that high MMP-9 and low MMP-2 levels are observed in a bupivacaine-injured sciatic nerve. ese ndings, along with histopathological results, suggest that bupivacaine induces intense in ammation, with in ltrated macrophages and other in ammatory cells, and with low levels of brocytes. In summary, these ndings con rm that the attraction of mast cells to the injection site has a role in initiating intense in ammation in bupivacaine-induced neurotoxicity.
It has been reported that degranulation of mast cells exacerbates in ammation in bupivacaine-injected tissue. Nonetheless, sodium cromolate inhibits degranulation of mast cells; therefore, the number of neutrophils recruited to the bupivacaine-injected site is decreased [5] . Studies in animal models indicate that stabilized mast cells are present in the early stages improves wound healing [34] . Histamine is used as a marker of mast cell degranulation and this histamine release from the mast cells is inhibited by tryptase and chymase inhibitors [35, 36] . Both tryptase and chymase originate from mast cell granules have crucial roles in the recruitment of in ammatory cells to an injury [37] [38] [39] [40] . It has also been reported that clonidine, an alpha-2 adrenoceptor agonist, inhibits histamine release and degranulation of mast cells [15, 16] . Another study reported that dexmedetomidine, a potent alpha-2 adrenoceptor agonist, has an eight times higher a nity for the alpha-2 adrenoceptor than clonidine [19] . All the literature presented so far suggests that dexmedetomidine may be a strong stabilizer of mast cells and may inhibit in ammation by blocking degranulation. us, the mast cell stabilizing potential of dexmedetomidine may explain its protective e ect in bupivacaineinduced sciatic nerve injury. Although bupivacaine-induced neurotoxicity is a rare adverse e ect seen in peripheral nerve blocks, it may be very serious and frequent in patients with diseases such as diabetes mellitus and accompanying neuropathy. In these patients, dexmedetomidine may be the choice of drug as an adjuvant. In addition, the method presented here may be a good model for the study of neuropathy.
Limitations is study focused on biochemical and histopathological ndings. ere was no neurobehavioral examination of the rats; therefore, it is hard to make a full assessment of clinical importance of these ndings.
e dose of dexmedetomidine used in this study was adjusted according to previously published animal studies; however, it exceeds the dose appropriate for humans. ese ndings should be replicated in lower doses.
It is speculated that dextmedetomidine e ect on mast cell may depend on alpha-2 adrenoreceptor although this hypothesis was not tested with an antagonist agent.
Conclusion
Both bupivacaine and dexmedetomidine attract mast cells to the injection region of the sciatic nerve: bupivacaine results in in ammation and nerve injury, whereas dexmedetomidine does not. It seems that the neuroprotective e ect of dexmedetomidine depends on its mast cell modulating potential. us, our ndings suggest that dexmedetomidine, with its neuroprotective e ect, may be a suitable adjuvant for regional anesthesia.
